Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer

BMC Research Notes

Carmen Sílvia Bertuzzo³  Fernando Augusto de Lima Marson¹  José da Silva Nogueira Junior² 

[1] Pediatrics Department, Medical Genetics Department, University of Campinas – UNICAMP, Campinas, Brazil;Department of Genetics, Faculty of Medical Sciences, University of Campinas, P.O. Box: 6111, Campinas, SP 13081-970, Brazil;Department of Pediatrics, School of Medical Sciences, University of Campinas, P.O. Box: 6111, Campinas, SP 13081-970, Brazil

关键词: Hereditary breast cancer;    Sporadic;    Sporadic breast cancer;    Breast cancer;    Gene polymorphisms;    Thymidylate synthasel;   

Others  :  1165046
DOI  :  10.1186/1756-0500-5-676

 received in 2012-09-03, accepted in 2012-11-27,  发布年份 2012

【 摘 要 】

Background

Breast cancer (BC) is a genetic disorder characterized by growth and proliferation of breast cells in a disorderly. In Brazil, there are approximately 49.240 new cases of BC, every year. The BC etiology is still poorly understood. The BC can be sporadic (SBC) or hereditary (HBC). Recent studies have correlated gene polymorphisms with the BC, such as alterations in thymidylate synthase gene (TYMS), which are used to improve diagnosis and prevention of the disease. Polymorphisms in the TYMS gene 5’-UTR region, usually present reps double (2R) and/or triple (3R). Studies have shown that homozygous 3R/3R is overexpressed compared with 2R/2R genotype, and these polymorphic variations may contribute to individual susceptibility to the development of BC. In this context, the objective of this study was to evaluate the frequency of the TYMS 2R and 3R polymorphisms, comparing genotypic and allelic distribution with SBC and HBC patients.

Methods

In this study we included a total of 204 subjects, 70 with BC (33 with SBC, and 37 with HBC) and 134 healthy subjects (controls). The Polymerase Chain Reaction was the method used.

Results

Results demonstrated a high frequency of the 3R allele at BC, SBC, and HBC groups. The frequency of genotype 2R/3R was significantly higher in BC group. This work showed association between the 2R/3R variants (OR = 4.14, CI95% = 1.77-9.71) in the development of SBC, and 2R/2R (OR = 0.233, CI95% = 1.63-7.65) and 2R/3R (OR = 3.53, CI95% = 0.06-0.81) for developing HBC. To BC, there was association with the genotype 2R/3R (OR: 3.79, CI95% = 2.03-7.08).

Conclusion

Our results show relation to the development of BC in association with the analyzed polymorphisms.

【 授权许可】

   
2012 Junior et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]World Health Organization: Cancer. WHO; 2011. [Acess: 2011 Jul. 27]. Disponible: http://www.who.int/cancer/en/ webcite.
• [2]Zou YF, Wang F, Feng XL: The association between two polymorphisms in the TYMS gene and breast cancer risk: appraisal of a recent meta-analysis. Breast Cancer Res Treat 2011, 128(1):289-290.
• [3]Henríquez-Hernández LA, Murias-Rosales A, Hernández González A, Cabrera De León A, Díaz-Chico BN, Mori De Santiago M, Fernández Pérez L: Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: A case–control study. Oncol Rep 2009, 22(06):1425-1433.
• [4]Van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ: Distinction between hereditary and sporadic breast câncer on the basis of clinicopathological data. J Clin Pathol 2006, 59:611-617.
• [5]Van Diest PJ: No consent should be needed for using leftover body material for scientific purposes. BMJ 2002, 325:648-651.
• [6]Kenemans P, Verstraeten RA, Verheijen RHM: Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas 2004, 49:34-43.
• [7]Latimer JJ, Johnson JM, Kelly CM, Miles TD, Beaudry-Rodgers KA, Lalanne NA, Vogel VG, Kanbour-Shakir A, Kelley JL, Johnson RR, Grant SG: Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer. PNAS 2010, 107(50):21725-21730.
• [8]Henríquez-Hernández LA, Pérez LF, González AH, León AC, Díaz-Chico BN, Rosales AM: TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy. Cancer Epidemiol 2010, 34:490-493.
• [9]Jakobsen A, Nielsen NJ, Gyldenkerne N, Lindeberg J: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005, 23:1365-1369.
• [10]Lecomte T, Ferraz JM, Zinzindohoué F, Loriot MA, Tregouet DA, Landi B, Berger A, Cugnenc PH, Jian R, Beaune P, Laurent-Puig P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004, 10:5880-5888.
• [11]Wang J, Wang B, Bi J, Di J: The association between two polymorphisms in the TYMS gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2011, 128:203-209.
• [12]Zhai X, Gao J, Hu Z, Tang J, Qin J, Wang S, Wang X, Jin G, Liu J, Chen W, Chen F, Wang X, Wei Q, Shen H: Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case–control analysis. BMC Cancer 2006, 6:138. BioMed Central Full Text
• [13]Feng IJ, Radivoyevitch T: SNP-SNP interactions between dNTP supply enzymes and mismatch DNA repair in breast cancer. Proc Ohio Collab Conf Bioinform 2009, 15:123-128.
• [14]Calascibetta A, Contino F, Feo S, Gulotta G, Cajozzo M, Antona A, Sanguedolce G, Sanguedolce R: Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-fluorouracil drug response. J of Nucleic Acids 2009, 2010:1-4.
• [15]Fariña-Sarasqueta A, Gosens MJEM, Moerland E, Lijnschoten IV, Lemmens VEPP, Slooter GD, Rutten HJT, van den Brule AJC: TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients. Anal Cell Pathol/Cell Oncol 2010, 33:1-11.
• [16]Bonadia LC: Estudo de associação entre polimorfismos em genes que codificam enzimas participantes do metabolismo do folato e a formação de embriões com aberrações cromossômicas. Campinas: Dissertação [Mestrado em Ciências Médicas]. Departamento de Genética Médica, Universidade Estadual de Campinas; 2004.
• [17]SPSS 17.0 For windows (computer program). statistical package for social science (SPSS). release version 17.0.1. Chicago (IL): SPSS. Incorporation. 2011. Available from: http://www.spss.com webcite.
• [18]Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
• [19]Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF: A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999, 8:843-854.
• [20]Kawakita D, Matsuo K, Sato F, Oze I, Hosono S, Ito H, Watanabe M, Yatabe Y, Hanai N, Hasegawa Y, Tajima K, Murakami S, Tanaka H: Association between dietary folate intake and clinical outcome in head and neck squamous cell carcinoma. Ann Oncol 2012, 23(1):186-192.
• [21]Ghosh S, Winter JM, Patel K, Kern SE: Reexamining a proposal thymidylate synthase 5’-untranslated region as a regulator of translation efficiency. Cancer Biol Ther 2011, 12(8):750-755.
• [22]Brown KS, Kluijtmans LA, Young IS, McNulty H, Mitchell LE, Yarnell JW, Woodside JV, Boreham CA, McMaster D, Murray L, Strain JJ, Whitehead AS: The thymidylate synthase tandem repeat polymorphism is not associated with homocysteine concentrations in healthy young subjects. Hum Genet 2004, 114:182-185.
• [23]Düzgün N, Duman T, Morris Y, Tutkak H, Köse K, Ertuğrul E, Aydintuğ OT: Thymidylate synthase genotype and serum concentrations of homocysteine and folate in Behçet’s disease. Clin Rheumatol 2008, 27:1221-1225.
• [24]Uchida K, Hayashi K, Kawakami K, Schneider S, Yochim JM, Kuramochi H, Takasaki K, Danenberg KD, Danenberg PV: Polymorphism in the TS gene survival in individuals heterozygous for a 28-bp locus on chromosome 18 affects tumor response and loss of heterozygosity at the thymidylate synthase (TS). Clin Cancer Res 2004, 10:433-439.
• [25]Brody JR, Hucl T, Gallmeier E, Winter JM, Kern SE, Murphy KM: Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. Cancer Res 2006, 66:9369-9373.
• [26]Hur H, Kang J, Kim NK, Min BS, Lee KY, Shin SJ, Keum KC, Choi J, Kim H, Choi SH, Lee MY: Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. J Radiat Oncol Biol Phys 2011, 81(3):669-676.
• [27]Tan BR, Thomas F, Myerson RJ, Zehnbauer B, Trinkaus K, Malyapa RS, Mutch MG, Abbey EE, Alyasiry A, Fleshman JW, McLeod HL: Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma. J Clin Oncol 2011, 45:1-10.
• [28]Tanaka F, Wada H, Fukui Y, Fukushima M: Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Ann Oncol 2011, 22(8):1791-1797.
• [29]Weekes CD, Nallapareddy S, Rudek MA, Norris-Kirby A, Laheru D, Jimeno A, Donehower RC, Murphy KM, Hidalgo M, Baker SD, Messersmith WA: Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Invest New Drugs 2011, 29:1057-1065.
• [30]Wynes MW, Dziadziuszko R, Singh S, Ranger-Moore J, Szostakiewicz B, Dziadziuszko K, Jassem J, Hirsch FR: Thymidylate synthase (TS) gene copy number in NSCLC. J Clin Oncol 2010, 28(15):21063-21067.
• [31]Skibola CF, Forrest MS, Coppedé F, Agana L, Hubbard A, Smith MT, Bracci PM, Holly EA: Polymorphisms and haplotypes in folate-metabolizing genes and risk of non-Hodgkin lymphoma. Blood 2004, 104(7):2055-2062.
• [32]Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C: Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. J Clin Oncol 2006, 24(25):4062-4068.
• [33]Kawakami K, Omura K, Kanehira E, Wa tanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999, 19(4B):3249-3252.
• [34]Trinh BN, Ong CN, Coetzee GA, Yu MC, Laird PW: Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. Hum Genet 2002, 111(3):299-302.
• [35]Xi Y, Nakajima G, Schmitz JC, Chu E, Ju J: Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genom 2006, 7:68-83. BioMed Central Full Text
• [36]Calascibetta A, Contino F, Feo S, Gulotta G, Cajozzo M, Antona A, Sanguedolce G, Sanguedolce R: Analysis of the thymidylate synthase gene structure in colorectal cancer patients and its possible relation with the 5-fluorouracil drug response. J of Nucl Acids 2010, 2010:1-4.
• [37]Mauritz R, Giovannetti E, Beumer IJ, Smid K, Van Groeningen CJ, Pinedo HM, Peters GJ: Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. Clin Colorectal Cancer 2009, 8(3):146-154.
• [38]Gusella M, Padrini R: G > C SNP of thymidylate synthase with respect to colorectal cancer. Pharmacogenomics 2007, 8(8):985-996.
• [39]Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V: UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. BJ of Cancer 2010, 103:581-589.
• [40]Ministério da Saúde. Instituto Nacional de Câncer: Parâmetros técnicos para programação de ações de detecção precoce do câncer de mama. Recomendações para gestores estaduais e municipais. Edited by RJ Rio de Janeiro. Ministério da Saúde; 2006. [Acess: 2011 dez. 13]. Avaiable: http://www.inca.gov.br/inca/Arquivos/publicacoes/Parametrostexto.pdf webcite.